Medically advised aspirin use lower in 2021 than 2012 to 2017
Jun 24, 2024
Compared with 2012 to 2017, in 2021, medically advised aspirin use for primary prevention was lower (19.3 versus 27.6 to 31.2% among adults aged 60 to 69 years; 30.6 versus 38.35 to 41.6% among those aged...
Fewer adults eligible for statins with PREVENT equations
Jun 21, 2024
Compared with the pooled cohort equations, the mean estimated 10-year ASCVD risk was lower using the PREVENT equations across all age, sex and racial subgroups, with the largest difference seen for Black...
Reteplase superior to alteplase within 4.5 hours of ischemic stroke
Jun 20, 2024
Reteplase was more likely to result in excellent functional outcome than alteplase for ischemic stroke within 4.5 hours of symptom onset.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Medicare to cover Wegovy when patients also have heart disease
Mar 22, 2024
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
2011 to 2020 saw increase in annual prescription meds expenditures
Apr 15, 2024
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.